Publications by authors named "Rema Iyer"
Article Synopsis
- * Researchers found that a fusion protein called SS18-SSX drives the cancer's growth, and by analyzing cancer data, they identified that SUMO2 is a key gene that SySa cells rely on to survive.
- * The drug TAK-981, which inhibits SUMO2, was shown to effectively stop SySa cell growth and reverse harmful gene activities tied to the cancer, suggesting it could be a promising targeted treatment option as it is already in clinical trials for other cancers.
Designing binders to target undruggable proteins presents a formidable challenge in drug discovery, requiring innovative approaches to overcome the lack of putative binding sites. Recently, generative models have been trained to design binding proteins via three-dimensional structures of target proteins, but as a result, struggle to design binders to disordered or conformationally unstable targets. In this work, we provide a generalizable algorithmic framework to design short, target-binding linear peptides, requiring only the amino acid sequence of the target protein.
View Article and Find Full Text PDFBritish Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice.
Eur J Obstet Gynecol Reprod Biol
January 2021
Article Synopsis
- Cervical cancer rates are decreasing in many countries, thanks to screening programs and immunization, with expectations of further reduction in the coming decades.
- This guideline focuses on managing invasive cervical cancer, detailing diagnosis, imaging (including new technologies), and treatment options like surgery for smaller tumors and (chemo)-radiation for advanced cases.
- It also covers fertility-sparing procedures, special cases (like cancer during pregnancy), long-term effects, and ways to improve patient quality of life.
Background: There is limited evidence on the costs of Endometrial Cancer (EC) by stage of disease. We estimated the long-term secondary care costs of EC according to stage at diagnosis in an English population-based cohort.
Methods: Women participating in UKCTOCS and diagnosed with EC following enrolment (2001-2005) and prior to 31st Dec 2009 were identified to have EC through multiple sources.
Human carbonic anhydrase II (CA II), a zinc metalloenzyme, was screened against 960 structurally diverse, biologically active small molecules. The assay monitored CA II esterase activity against the substrate 4-nitrophenyl acetate in a format allowing high-throughput screening. The assay proved to be robust and reproducible with a hit rate of approximately 2%.
View Article and Find Full Text PDF